Exelixis Set to Announce Q4 Earnings on February 10th
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy EXEL?
Source: seekingalpha
- Earnings Announcement: Exelixis (EXEL) is set to announce its Q4 earnings on February 10th after market close, with consensus EPS estimated at $0.81, reflecting a significant 47.3% year-over-year growth, indicating the company's robust performance in the oncology sector.
- Revenue Expectations: The revenue estimate for Q4 stands at $601.1 million, representing a 6.1% year-over-year increase; however, the revenue forecast has faced eight downward revisions in the last three months, suggesting some market volatility.
- Performance Track Record: Over the past two years, Exelixis has exceeded EPS estimates 88% of the time and revenue estimates 75% of the time, showcasing its strong operational capabilities and potentially attracting more investor interest ahead of the earnings report.
- Analyst Rating Changes: Despite BofA downgrading Exelixis to Underperform due to valuation concerns and a lack of catalysts, the anticipation surrounding a potential FDA approval could still drive the stock price higher, reflecting a nuanced market perspective on the company's future prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EXEL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EXEL
Wall Street analysts forecast EXEL stock price to rise
16 Analyst Rating
7 Buy
8 Hold
1 Sell
Moderate Buy
Current: 42.700
Low
30.00
Averages
44.09
High
52.00
Current: 42.700
Low
30.00
Averages
44.09
High
52.00
About EXEL
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Exelixis Posts Strong Earnings—Could New Highs Be on the Horizon?
Earnings Report Overview: Exelixis, Inc. reported earnings per share of 94 cents, exceeding consensus estimates by 27%, but its revenue of $598.66 million fell short of expectations, leading to a 2% decline in stock price.
Future Growth Strategy: The company is focusing on expanding its franchise strategy and investing in research and development, particularly around its drug candidate, zanidatamab, which targets colorectal cancer.
Market Positioning: Exelixis is transitioning from a single-product company to a multi-franchise player in oncology, with forecasts suggesting potential peak annual sales of $5 billion if zanidatamab receives regulatory approval.
Investment Outlook: Analysts maintain an equal weight rating on Exelixis stock, with price targets being raised, indicating confidence in the company's growth potential despite current stock consolidation patterns.
See More
Exelixis Q4 2025 Earnings Call Highlights
- Strong Financial Performance: Exelixis reported total revenues of approximately $599 million for Q4 2025, with cabozantinib product revenues at $546.6 million, demonstrating sustained growth in the oncology sector and reinforcing its market leadership.
- Product Line Expansion: CEO Michael Morrissey highlighted that cabozantinib's U.S. net revenues exceeded $100 million for neuroendocrine tumors in 2025, indicating the strategic success of the company's diversified oncology treatment portfolio.
- Optimistic Future Outlook: CFO Christopher Senner reiterated the 2026 financial guidance, estimating gross to net margins between 31% and 32%, reflecting confidence in future growth while planning to continue share repurchases to enhance shareholder value.
- Market Dynamics Monitoring: Management expressed concerns about variability in 340B purchasing behavior, anticipating continued fluctuations in 2026 that could impact net revenues, highlighting the complexities and uncertainties of market competition.
See More
EXELIXIS Q4 ADJUSTED EPS REACHES USD 0.94, BEATING IBES ESTIMATE OF USD 0.79
Earnings Report: EXELIXIS reported a Q4 adjusted EPS of $0.94, indicating strong financial performance.
Comparison with Estimates: The reported EPS surpassed the IBES estimate of $0.79, reflecting better-than-expected results.
See More
Exelixis Q4 Earnings Beat Expectations with Strong Guidance
- Earnings Beat: Exelixis reported a Q4 non-GAAP EPS of $0.97, exceeding expectations by $0.16, which reflects improved profitability and may bolster investor confidence moving forward.
- Revenue Miss: The total revenue of $598.66 million, while up 5.6% year-over-year, fell short of the consensus estimate by $2.44 million, indicating potential pressures from increased market competition affecting sales.
- 2026 Guidance Maintained: Exelixis is maintaining its financial guidance for fiscal year 2026, projecting total revenues between $2.525 billion and $2.625 billion, which demonstrates confidence in future growth despite market expectations of $2.60 billion.
- R&D Investment Plans: The company plans to allocate $875 million to $925 million for research and development, underscoring its ongoing commitment to innovative drug development, which could lay the groundwork for future product line expansions.
See More
Exelixis Set to Announce Q4 Earnings on February 10th
- Earnings Announcement: Exelixis (EXEL) is set to announce its Q4 earnings on February 10th after market close, with consensus EPS estimated at $0.81, reflecting a significant 47.3% year-over-year growth, indicating the company's robust performance in the oncology sector.
- Revenue Expectations: The revenue estimate for Q4 stands at $601.1 million, representing a 6.1% year-over-year increase; however, the revenue forecast has faced eight downward revisions in the last three months, suggesting some market volatility.
- Performance Track Record: Over the past two years, Exelixis has exceeded EPS estimates 88% of the time and revenue estimates 75% of the time, showcasing its strong operational capabilities and potentially attracting more investor interest ahead of the earnings report.
- Analyst Rating Changes: Despite BofA downgrading Exelixis to Underperform due to valuation concerns and a lack of catalysts, the anticipation surrounding a potential FDA approval could still drive the stock price higher, reflecting a nuanced market perspective on the company's future prospects.
See More
Exelixis' NDA for Zanzalintinib Accepted by FDA for Review
- FDA Review Progress: Exelixis announced that its New Drug Application (NDA) for zanzalintinib in combination with atezolizumab for metastatic colorectal cancer has been accepted for review by the FDA, with a target action date of December 3, 2026, marking a significant advancement in cancer treatment.
- Clinical Trial Results: The phase 3 STELLAR-303 trial demonstrated that the combination of zanzalintinib and atezolizumab significantly improved median overall survival and reduced the risk of death, highlighting its potential in treating metastatic colorectal cancer.
- Market Demand Response: The introduction of zanzalintinib addresses the urgent need for effective therapies for previously treated metastatic colorectal cancer patients, potentially enhancing Exelixis' competitive position in the oncology market.
- Future Outlook: Exelixis plans to collaborate closely with the FDA to expedite the review process for zanzalintinib, which, if approved, could provide new hope for patients with metastatic colorectal cancer and further solidify the company's leadership in innovative drug development.
See More
Exelixis Posts Strong Earnings—Could New Highs Be on the Horizon?
Earnings Report Overview: Exelixis, Inc. reported earnings per share of 94 cents, exceeding consensus estimates by 27%, but its revenue of $598.66 million fell short of expectations, leading to a 2% decline in stock price.
Future Growth Strategy: The company is focusing on expanding its franchise strategy and investing in research and development, particularly around its drug candidate, zanidatamab, which targets colorectal cancer.
Market Positioning: Exelixis is transitioning from a single-product company to a multi-franchise player in oncology, with forecasts suggesting potential peak annual sales of $5 billion if zanidatamab receives regulatory approval.
Investment Outlook: Analysts maintain an equal weight rating on Exelixis stock, with price targets being raised, indicating confidence in the company's growth potential despite current stock consolidation patterns.
See More
Exelixis Q4 2025 Earnings Call Highlights
- Strong Financial Performance: Exelixis reported total revenues of approximately $599 million for Q4 2025, with cabozantinib product revenues at $546.6 million, demonstrating sustained growth in the oncology sector and reinforcing its market leadership.
- Product Line Expansion: CEO Michael Morrissey highlighted that cabozantinib's U.S. net revenues exceeded $100 million for neuroendocrine tumors in 2025, indicating the strategic success of the company's diversified oncology treatment portfolio.
- Optimistic Future Outlook: CFO Christopher Senner reiterated the 2026 financial guidance, estimating gross to net margins between 31% and 32%, reflecting confidence in future growth while planning to continue share repurchases to enhance shareholder value.
- Market Dynamics Monitoring: Management expressed concerns about variability in 340B purchasing behavior, anticipating continued fluctuations in 2026 that could impact net revenues, highlighting the complexities and uncertainties of market competition.
See More
EXELIXIS Q4 ADJUSTED EPS REACHES USD 0.94, BEATING IBES ESTIMATE OF USD 0.79
Earnings Report: EXELIXIS reported a Q4 adjusted EPS of $0.94, indicating strong financial performance.
Comparison with Estimates: The reported EPS surpassed the IBES estimate of $0.79, reflecting better-than-expected results.
See More
Exelixis Q4 Earnings Beat Expectations with Strong Guidance
- Earnings Beat: Exelixis reported a Q4 non-GAAP EPS of $0.97, exceeding expectations by $0.16, which reflects improved profitability and may bolster investor confidence moving forward.
- Revenue Miss: The total revenue of $598.66 million, while up 5.6% year-over-year, fell short of the consensus estimate by $2.44 million, indicating potential pressures from increased market competition affecting sales.
- 2026 Guidance Maintained: Exelixis is maintaining its financial guidance for fiscal year 2026, projecting total revenues between $2.525 billion and $2.625 billion, which demonstrates confidence in future growth despite market expectations of $2.60 billion.
- R&D Investment Plans: The company plans to allocate $875 million to $925 million for research and development, underscoring its ongoing commitment to innovative drug development, which could lay the groundwork for future product line expansions.
See More
Exelixis Set to Announce Q4 Earnings on February 10th
- Earnings Announcement: Exelixis (EXEL) is set to announce its Q4 earnings on February 10th after market close, with consensus EPS estimated at $0.81, reflecting a significant 47.3% year-over-year growth, indicating the company's robust performance in the oncology sector.
- Revenue Expectations: The revenue estimate for Q4 stands at $601.1 million, representing a 6.1% year-over-year increase; however, the revenue forecast has faced eight downward revisions in the last three months, suggesting some market volatility.
- Performance Track Record: Over the past two years, Exelixis has exceeded EPS estimates 88% of the time and revenue estimates 75% of the time, showcasing its strong operational capabilities and potentially attracting more investor interest ahead of the earnings report.
- Analyst Rating Changes: Despite BofA downgrading Exelixis to Underperform due to valuation concerns and a lack of catalysts, the anticipation surrounding a potential FDA approval could still drive the stock price higher, reflecting a nuanced market perspective on the company's future prospects.
See More
Exelixis' NDA for Zanzalintinib Accepted by FDA for Review
- FDA Review Progress: Exelixis announced that its New Drug Application (NDA) for zanzalintinib in combination with atezolizumab for metastatic colorectal cancer has been accepted for review by the FDA, with a target action date of December 3, 2026, marking a significant advancement in cancer treatment.
- Clinical Trial Results: The phase 3 STELLAR-303 trial demonstrated that the combination of zanzalintinib and atezolizumab significantly improved median overall survival and reduced the risk of death, highlighting its potential in treating metastatic colorectal cancer.
- Market Demand Response: The introduction of zanzalintinib addresses the urgent need for effective therapies for previously treated metastatic colorectal cancer patients, potentially enhancing Exelixis' competitive position in the oncology market.
- Future Outlook: Exelixis plans to collaborate closely with the FDA to expedite the review process for zanzalintinib, which, if approved, could provide new hope for patients with metastatic colorectal cancer and further solidify the company's leadership in innovative drug development.
See More
